Edgar Filing: TANDEM DIABETES CARE INC - Form 3

TANDEM DIABETES CARE INC Form 3 November 13, 2013 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and A Person <u>*</u> Halak Bi		orting	 Date of Event Requiring Statement (Month/Day/Year) 	3. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC [TNDM]					
(Last) C/O DOMA LLC, ONI SQUARE PRINCETO	(First) IN ASSOC E PALMER (Street)		11/13/2013	Person(s) to I	x all applicable) rX10% (Other	Filed(Month/Day/Year) Owner 6. Individual or Joint/Group			
						Reporting Person			
(City)	(State)	(Zip)	Table I - I	Non-Deriva	tive Securitie	es Beneficially Owned			
1.Title of Secu (Instr. 4)	rity		2. Amount of Beneficially (Instr. 4)		Ownership	4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Reminder: Rep owned directly	or indirectly. Perso inform requir	ns who res ation conta ed to respo	ach class of securities benefic pond to the collection of ained in this form are no ond unless the form disp MB control number.	t s	SEC 1473 (7-02))			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									

1. Title of Derivative Security (Instr. 4)	2		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date		Amount or	Security: Direct (D)		

OMB APPROVAL

OMB 3235-0104 Number: January 31, 2005 Estimated average burden hours per response... 0.5

				Shares		or Indirect (I) (Instr. 5)	
Series B Preferred Stock	(1)	(1)	Common Stock	356,111	\$ <u>(1)</u>	Ι	By Domain Partners VII, L.P.
Series C Preferred Stock	(1)	(1)	Common Stock	549,833	\$ <u>(1)</u>	Ι	By Domain Partners VII, L.P.
Series D Preferred Stock	(1)	(1)	Common Stock	2,283,114	\$ <u>(1)</u>	Ι	By Domain Partners VII, L.P.
Warrant to Purchase Series D Preferred Stock	(2)	(2)	Series D Preferred Stock (3)	590,403 <u>(3)</u>	\$ 4.4 <u>(3)</u>	Ι	By Domain Partners VII, L.P.
Series B Preferred Stock	(1)	(1)	Common Stock	6,071	\$ <u>(1)</u>	Ι	By DP VII Associates, L.P. <u>(4)</u>
Series C Preferred Stock	(1)	(1)	Common Stock	9,378	\$ <u>(1)</u>	Ι	By DP VII Associates, L.P. <u>(4)</u>
Series D Preferred Stock	(1)	(1)	Common Stock	38,941	\$ <u>(1)</u>	Ι	By DP VII Associates, L.P. <u>(4)</u>
Warrant to Purchase Series D Preferred Stock	(5)	(5)	Series D Preferred Stock (3)	10,068 <u>(3)</u>	\$ 4.4 <u>(3)</u>	Ι	By DP VII Associates, L.P. (4)

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Halak Brian K C/O DOMAIN ASSOCIATES, LLC ONE PALMER SQUARE PRINCETON, NJ 08542	Â	ÂX	Â	Â	
Signatures					
/s/ Kathleen K. Schoemaker, Attorney-in-Fact	11/13/2013				
**Signature of Reporting Person		Date			

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

All outstanding shares of the Issuer's preferred stock will automatically convert into Common Stock upon the closing of the Issuer's initial
 public offering (the "IPO"), for no additional consideration. The preferred stock has no expiration date. The Common Stock equivalents of the preferred stock reflect the 1 for 1.6756 reverse split of the Common Stock effected in November 2013.

Edgar Filing: TANDEM DIABETES CARE INC - Form 3

(2) The Warrant is immediately exercisable and expires as follows: 362,965 shares on 8/17/21; 90,741 shares on 5/25/22; and 136,697 shares on 7/17/22.

Upon the closing of the IPO the Warrants to purchase Series D Preferred Stock will automatically convert into Warrants to purchase the number of shares of Common Stock that the Series D Preferred Stock underlying the Warrants will convert into, subject to the reverse split described in footnote (1), and the exercise price will accordingly adjust to \$7.37 per share.

The Reporting Person is a Managing Member of One Palmer Square Associates VII, LLC, which is the sole general partner of Domain Partners VII, L.P. and DP VII Associates, L.P. Pursuant to Instruction (5)(b)(iv) of Form 3, the Reporting Person has elected to report as

- (4) indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- (5) The Warrant is immediately exercisable and expires as follows: 6,190 shares on $\frac{8}{17}$; 1,547 shares on $\frac{5}{25}$; and 2,331 shares on $\frac{7}{17}$; 1,747 shares on $\frac{5}{25}$; and 2,331 shares on $\frac{5}{25}$; and 2,331; and 3,31 shares on $\frac{5}{25}$; and 3,31; and 3,31; and 3,31 shares on $\frac{5}{25}$; and 3,31; and 3,31; and 3,31; a

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.